Health News Releases

  • Today December 16
January 04, 2022 21:05
ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial eval
January 04, 2022 09:55
Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant
Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double
December 31, 2021 14:10
LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis
LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) for the treatment of moderate-to-severe atop
December 27, 2021 11:40
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
December 23, 2021 16:30
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 trial, which showed spesolimab, a first-in-class investi
December 23, 2021 14:30
Xlear Files Legal Response to Government’s Lawsuit
Today, Xlear Inc. filed the company’s response to a Department of Justice lawsuit alleging violations of the Federal Trade Commission Act, among other allegations. The company denied all the Governmen
December 22, 2021 14:40
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response
December 22, 2021 10:30
Covetrus Announces New Structure, Focus and Strength within Europe
Covetrus® (Nasdaq: CVET), a global leader in animal-health technology and services, today announced a new organizational structure within Northern and Central Europe to execute the company’s three-yea
December 21, 2021 17:30
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with e
December 21, 2021 17:10
The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Disease, Confirmed in a Recent Independent Study
A recently published research article in Nature Aging by a Cleveland Clinic Genomic Medicine Institute (GMI) research team, led by Feixiong Cheng, Ph.D., entitled “Endophenotype-based in silico networ
December 21, 2021 17:00
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced that the US F
December 21, 2021 11:05
Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment
December 20, 2021 15:40
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settl
December 20, 2021 14:15
TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations
Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recomm
December 16, 2021 15:30
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service
December 15, 2021 16:30
PCI Pharma Services Announces the Closing of Its Acquisition of LSNE
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the closing of the previously announced acquisition of Lyophilization Services o
December 15, 2021 13:50
BostonGene and NEC Announce Global Partnership
BostonGene Corporation and NEC Corporation (NEC; TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer BostonGene Tumor PortraitTM Tests in key in
December 14, 2021 17:05
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty
December 14, 2021 17:00
Retrace AV Launches New Paint Product That Destroys SARS-CoV-2, the COVID-19 Virus Within 30 Minutes
Billions of people around the world are attempting to return to workplaces, schools and social spaces. Governments & business owners need to do everything they can to boost confidence and let consumer
December 14, 2021 11:30
Organon Completes Acquisition of Forendo Pharma
Organon (NYSE: OGN), a global women’s healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in
December 14, 2021 11:10
New Study Suggests That Masimo SedLine® Brain Function Monitoring May Aid Early Identification of Patients at Risk of Developing Postoperative Delirium
Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in Anesthesia & Analgesia in which Dr. Claudia Spies and colleagues investigated the relationship between parameters
December 13, 2021 17:31
Vifor Pharma comments on media speculation
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Un
December 13, 2021 14:49
KOREA PACK & ICPI WEEK (Int’l Cosmetic and Pharmaceutical Industry Week) 2022 to Provide O2O Service Connecting Offline Exhibition to the Online Business Platform
KOREA PACK and concurrent event ICPI WEEK (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022. KOREA PACK and ICPI WEEK, the largest packaging, cosmetic and phar
December 13, 2021 14:35
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult pat
December 13, 2021 10:00
Researchers to Investigate the Gut-Brain Axis in Soldiers With Microba’s Technology
Leading Australian universities will explore the ‘cognobiome’ of soldiers using Microba Life Science’s analysis platform to discover opportunities for improving cognitive and physiological performance
25 per page50 per page75 per page100 per page